Turnstone Biologics (NASDAQ:TSBX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) Head-To-Head Comparison

Turnstone Biologics (NASDAQ:TSBX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Risk & Volatility

Turnstone Biologics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Turnstone Biologics and Quantum Genomics Société Anonyme, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turnstone Biologics	1	0	1	0	2.00
Quantum Genomics Société Anonyme	0	0	0	0	0.00

Turnstone Biologics currently has a consensus price target of $2.13, suggesting a potential upside of 377.53%. Given Turnstone Biologics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Turnstone Biologics is more favorable than Quantum Genomics Société Anonyme.

Profitability

This table compares Turnstone Biologics and Quantum Genomics Société Anonyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Turnstone Biologics	N/A	-105.99%	-87.27%
Quantum Genomics Société Anonyme	N/A	N/A	N/A

Institutional and Insider Ownership

52.5% of Turnstone Biologics shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Turnstone Biologics and Quantum Genomics Société Anonyme”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turnstone Biologics	$19.31 million	0.53	-$55.20 million	($3.24)	-0.14
Quantum Genomics Société Anonyme	N/A	N/A	N/A	N/A	N/A

Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Turnstone Biologics.

Summary

Turnstone Biologics beats Quantum Genomics Société Anonyme on 7 of the 9 factors compared between the two stocks.

About Turnstone Biologics

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

About Quantum Genomics Société Anonyme

Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.